Cerecor on go with study of CERC-002 in COVID-19 patients

Cerecor (NASDAQ:CERC) has received FDA clearance to proceed with a proof-of-concept clinical trial of its anti-LIGHT monoclonal antibody CERC-002 in patients with COVID-19 cytokine storm-induced Acute Respiratory Distress Syndrome (ARDS).

The study will assess the efficacy and safety of CERC-002 and will enroll ~82 subjects. The first patient is expected to enroll in June, and top line data are expected in Q4.

The primary objective is to demonstrate that treatment with CERC-002 results in fewer instances of respiratory failure and death versus the standard of care.

https://seekingalpha.com/news/3578190-cerecor-on-go-study-of-cercminus-002-in-covidminus-19-patients